An Integrated Approach Towards Pandemic
Technology transfer programmes are one of the ways pharmaceutical companies can play a role in charting a path toward pandemic preparedness. However, they need to be adapted to be relevant to the specific regions. Subject matter experts including Hilleman
Laboratories and our partners need to have a good understanding of the contextual differences between developed and developing countries and create training materials that are relevant for specific markets.
Additionally, technology transfer programmes require consistent upskilling so that countries in both developed and developing markets are trained to work with new technologies.
Trainers and trainees will need to work hand-in-hand to track learning progress so that LMICs can fully benefit from these programmes.
Last but not least, technology transfer remains a challenging process due to its complexity, involvement of a large team of experts, time investment, and the right regulatory registrations—all of which need to be set against the highest quality standards
as required of vaccine products.
Professional institutions such as the International Society of Pharmaceutical Engineering (ISPE), organisations such as the Global Alliance for Vaccines and Immunisations (GAVI), Coalition for Epidemic Preparedness Innovations (CEPI), or Parenteral Drug
Association (PDA) are best placed to lead collaborative efforts, but pharmaceutical players can also proactively build long-term partnerships with like-minded organisations that are part of the larger ecosystem, working
to develop and produce new and improved vaccines to positively impact global public health.